Prasad: FDA Committed To Accelerated Approvals Despite CHIKV Pause

By Jessica Karins / June 9, 2025 at 2:35 PM

Top FDA biologics center officials say they remain committed to the accelerated approval pathway for rare, serious, and neglected diseases without available therapy despite a recent decision to pause administration of a chikungunya virus (CHIKV) vaccine, which had received accelerated approval for older adults, following severe adverse events.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.